Literature DB >> 16267612

Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer.

Marcin Radosław Lener1, Dorota Oszutowska, Jennifer Castaneda, Grzegorz Kurzawski, Janina Suchy, Katarzyna Nej-Wołosiak, Tomasz Byrski, Tomasz Huzarski, Jacek Gronwald, Anna Szymańska, Jolanta Szymańska-Pasternak, Tomasz Grodzki, Piotr Serwatowski, Grzegorz Bre Borowicz, Rodney J Scott, Jan Lubiński.   

Abstract

Both breast and lung cancers are common malignancies and within the context of known genetic predispositions to breast cancer, no association has been made in linking the two diseases together. This does not exclude the possibility that such associations may exist that lie outside the known high-risk breast cancer families. To examine the likelihood of common genetic factors that could influence the risk of disease, two sets of consecutively collected tumor groups were examined for the 3020insC mutation in the NOD2/CARD15 gene. A total of 4107 consecutively collected breast cancer patients were assessed for the prevalence of the 3020insC mutation and compared to a consecutively collected series of 389 lung cancer patients and 2068 control samples. The results revealed that a proportion of breast cancer patients who had a first or a second degree relative diagnosed with lung cancer were more likely to harbour a change in NOD2/CARD15 compared to patients who had no relatives affected by lung cancer. Furthermore, this difference appeared to be specific to the breast and lung cancer subgroup since there was no difference in the frequency of the 3020insC allele in the consecutively collected lung cancer patients. In conclusion, it appears that the 3020insC mutation of the NOD2/CARD15 gene may be a genetic predisposing factor for aggregations of breast and lung cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16267612     DOI: 10.1007/s10549-005-9057-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

Review 1.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 2.  NOD2: ethnic and geographic differences.

Authors:  Juleen Cavanaugh
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

3.  Low-risk Genes and Multi-organ Cancer Risk in the Polish Population.

Authors:  Tadeusz Debniak; Cezary Cybulski; Grzegorz Kurzawski; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Janina Suchy; Bartłomiej Masojć; Marek Mierzejewski; Marcin Lener; Urszula Teodorczyk; Krzysztof Medrek; Elzbieta Złowocka; Ewa Grabowska-Kłujszo; Katarzyna Nej-Wołosiak; Anna Szymańska; Jolanta Szymańska-Pasternak; Joanna Matyjasik; Thierry van de Wetering; Anna Jakubowska; Oleg Oszurek; Aleksandra Tołoczko-Grabarek; Jennifer Castaneda; Rodney Scott; Steven A Narod; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2006-01-15       Impact factor: 2.857

4.  Multidrug-Resistance Related Long Non-Coding RNA Expression Profile Analysis of Gastric Cancer.

Authors:  Ying Wang; Kaichun Wu; Zhiping Yang; Qingchuan Zhao; Dongmei Fan; Po Xu; Yongzhan Nie; Daiming Fan
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

Review 5.  Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract.

Authors:  Evagelia Spanou; Polyxeni Kalisperati; Ioannis S Pateras; Alexandros Papalampros; Alexandra Barbouti; Athanasios G Tzioufas; Athanassios Kotsinas; Stavros Sougioultzis
Journal:  Front Genet       Date:  2017-05-29       Impact factor: 4.599

6.  The different roles of innate immune receptors in inflammation and carcinogenesis between races.

Authors:  Natsu Yamaguchi; Yoshimi Suzuki; M H Mahbub; Hidekazu Takahashi; Ryosuke Hase; Yasutaka Ishimaru; Hiroshi Sunagawa; Rie Watanabe; Yoshinobu Eishi; Tsuyoshi Tanabe
Journal:  Environ Health Prev Med       Date:  2017-10-11       Impact factor: 3.674

7.  The Impact of the NOD2/CARD15 Variant (3020insC) and PSMA6 Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma.

Authors:  S Zmorzyński; S Popek-Marciniec; W Styk; M Wojcierowska-Litwin; I Korszeń-Pilecka; A Szudy-Szczyrek; S Chocholska; M Hus; A A Filip
Journal:  Biomed Res Int       Date:  2020-06-06       Impact factor: 3.411

8.  NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome.

Authors:  Neema P Mayor; Bronwen E Shaw; J Alejandro Madrigal; Steven G E Marsh
Journal:  Bone Marrow Res       Date:  2012-10-18

9.  NOD2 polymorphisms associated with cancer risk: a meta-analysis.

Authors:  Jingwei Liu; Caiyun He; Qian Xu; Chengzhong Xing; Yuan Yuan
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

Review 10.  NOD-Like Receptors: Master Regulators of Inflammation and Cancer.

Authors:  Mansi Saxena; Garabet Yeretssian
Journal:  Front Immunol       Date:  2014-07-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.